Abstract
The previously unknown coronavirus that caused severe acute respiratory syndrome (SARS-CoV) affected more than 8,000 persons worldwide and was responsible for more than 700 deaths during the first outbreak in 2002-2003. For reasons unknown, the SARS virus is less severe and the clinical progression a great deal milder in children younger than 12 years of age. In contrast, the mortality rate can exceed 50% for persons at or above the age of 60. As part of the Sino-European Project on SARS Diagnostics and Antivirals (SEPSDA), an immune phage-display library is being created from convalescent patients in a phagemid system for the selection of single-chain fragment variables (scFv) antibodies recognizing the SARS-CoV.
Publication types
- Research Support, Non-U.S. Gov't
- Review
MeSH terms
- Antibodies, Viral / immunology*
- Antiviral Agents / immunology
- Antiviral Agents / therapeutic use*
- Enzyme-Linked Immunosorbent Assay
- Fluorescent Antibody Technique, Indirect
- Humans
- Immunoglobulin Fragments / immunology
- Peptide Library
- Serology
- Severe Acute Respiratory Syndrome / diagnosis*
- Severe Acute Respiratory Syndrome / immunology
- Severe Acute Respiratory Syndrome / therapy*
- Severe Acute Respiratory Syndrome / virology
- Severe acute respiratory syndrome-related coronavirus / genetics
- Severe acute respiratory syndrome-related coronavirus / immunology
- Severe acute respiratory syndrome-related coronavirus / isolation & purification*
Substances
- Antibodies, Viral
- Antiviral Agents
- Immunoglobulin Fragments
- Peptide Library